Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma.

about

An overview of cutaneous T cell lymphomas

P2860

Q26740306-133E68CC-0D27-40FC-9775-FBADB23061D1

P2860

Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma.

Item

http://www.wikidata.org/entity/Q40131573

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma.

@en

type

Item

label

Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma.

@en

prefLabel

Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma.

@en

P1476

Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma.

@en

P2093

Catherine Besner Morin

http://www.w3.org/2001/XMLSchema#string

David Roberge

http://www.w3.org/2001/XMLSchema#string

Gizelle Popradi

http://www.w3.org/2001/XMLSchema#string

Irina Turchin

http://www.w3.org/2001/XMLSchema#string

Kevin Pehr

http://www.w3.org/2001/XMLSchema#string

Tina Petrogiannis-Haliotis

http://www.w3.org/2001/XMLSchema#string

P2860

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions

WHO-EORTC classification for cutaneous lymphomas.

The role of retinoids and retinoic acid receptors in normal hematopoiesis.

Topical and systemic retinoid therapy for cutaneous T-cell lymphoma.

What's new in the management of cutaneous T-cell lymphoma?

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases.

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.

Retinoid regulation of interleukin-2 receptors on human T-cells.

Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials.

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.

P304

244-248

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1203475415626686

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26742957

http://www.w3.org/2001/XMLSchema#string

Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma.

about

P2860

P2860

Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698